Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6209-6216

  Dilda, Pierre J ^a   Decollogne, Stéphanie ^a   Weerakoon, Lakmini ^a   Norris, Murray D ^b   Haber, Michelle ^b   Allen, John D ^c   Hogg, Philip J ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^c CENTENARY INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (N ( PENICILLAMINYLACETYL)AMINO)PHENYLARSONOUS ACID; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; TRIPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BIOMIMETICS; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSOL; DOGS; ENDOTHELIAL CELLS; EXTRACELLULAR SPACE; FEMALE; HUMANS; MICE; MITOCHONDRIA; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350075458     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9008339     Document Type: Article

References (19)

1. Don, A. S.; Hogg, P. J. Mitochondria as cancer drug targets. Trends Mol. Med. 2004, 10, 372-378.
2. Don, A. S.; Kisker, O.; Dilda, P.; Donoghue, N.; Zhao, X.; Decollogne, S.; Creighton, B.; Flynn, E.; Folkman, J.; Hogg, P. J. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003, 3, 497-509.
3. Dilda, P. J.; Don, A. S.; Tanabe, K.M.; Higgins, V. J.; Allen, J. D.; Dawes, I.W.;Hogg, P. J.Mechanismof selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains. J. Natl. Cancer Inst. 2005, 97, 1539-1547.
4. Dilda, P. J.; Ramsay, E. E.; Corti, A.; Pompella, A.; Hogg, P. J. Metabolism of the tumor angiogenesis inhibitor 4-(N-(S-glutathionylacetyl) amino)phenylarsonous acid. J. Biol. Chem. 2008, 283, 35428-35434.
5. Halestrap, A. P.; McStay, G. P.; Clarke, S. J. The permeability transition pore complex: another view. Biochimie 2002, 84, 153-166.
6. Halestrap, A. P. What is the mitochondrial permeability transition pore? J. Mol. Cell. Cardiol. 2009, 46, 821-831.
7. McStay, G. P.; Clarke, S. J.; Halestrap, A. P. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem. J. 2002, 367, 541-548.
8. Murgia, M.; Giorgi, C.; Pinton, P.; Rizzuto, R. Controlling metabolism and cell death: at the heart of mitochondrial calcium signalling. J. Mol. Cell. Cardiol. 2009, 46, 781-788.
9. Adams, E.; Jeter, D.; Cordes, A. W.; Kolis, J. W. Chemistry of organometalloid complexes with potential antidotes: structure of an organoarsenic(III) dithiolate ring. Inorg. Chem. 1990, 29, 1500-1503.
10. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 2003, 306, 703-708.
11. Kool, M.; van der Linden, M.; de Haas, M.; Scheffer, G. L.; de Vree, J. M.; Smith, A. J.; Jansen, G.; Peters, G. J.; Ponne, N.; Scheper, R. J.; Elferink, R. P.; Baas, F.; Borst, P. MRP3,an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U.S.A 1999, 96, 6914-6919.
12. Evers, R.; Kool, M.; Smith, A. J.; van Deemter, L.; de Haas, M.; Borst, P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br. J. Cancer 2000, 83, 366-374. (Pubitemid 30453578)
13. Wielinga, P. R.; Reid, G.; Challa, E. E.; van der Heijden, I.; van Deemter, L.; de Haas, M.; Mol, C.; Kuil, A. J.; Groeneveld, E.; Schuetz, J. D.; Brouwer, C.; De Abreu, R. A.; Wijnholds, J.; Beijnen, J. H.; Borst, P. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol. Pharmacol. 2002, 62, 1321-1331.
14. Burkhart, C. A.; Watt, F.; Murray, J.; Pajic, M.; Prokvolit, A.; Xue, C.; Flemming, C.; Smith, J.; Purmal, A.; Isachenko, N.; Komarov, P. G.; Gurova, K. V.; Sartorelli, A. C.; Marshall, G. M.; Norris, M. D.; Gudkov, A. V.; Haber, M. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res. 2009, 69, 6573-6580.
15. Jedlitschky, G.; Leier, I.; Buchholz, U.; Barnouin, K.; Kurz, G.; Keppler, D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996, 56, 988-994. (Pubitemid 26065391)
16. Leslie, E. M.; Haimeur, A.; Waalkes, M. P. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 2004, 279, 32700-32708.
17. Allen, J. D.; Brinkhuis, R. F.; Wijnholds, J.; Schinkel, A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999, 59, 4237-4241.
18. Wolff, N. C.; Randle, D. E.; Egorin, M. J.; Minna, J. D.; Ilaria, R. L., Jr. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin. Cancer Res. 2004, 10, 3528-3534.
19. Weidner, N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat. 1995, 36, 169-180.